{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:25:36Z","timestamp":1787239536830,"version":"build-2736575974"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Ocular toxicity from anti-cancer drugs is frequently overlooked, largely because it is non-life-threatening, whereas clinical priorities often center on adverse events that pose immediate risks to survival. Antibody-drug conjugates (ADCs) have emerged as an important therapeutic modality in oncology, offering potent cytotoxicity against tumor cells through the targeted delivery of payloads. However, this potency also introduces a spectrum of toxicities, among which ocular toxicity has gained increasing attention. ADC-induced ocular toxicity can impair visual function and significantly compromise both quality of life and treatment adherence. This review compiles data on ocular toxicity reported during clinical development and postmarketing surveillance of all currently approved ADCs. This review analyzes the potential mechanisms underlying ADC-associated ocular toxicity and provides a detailed summary of the reported ocular adverse events and their incidence across approved ADCs. It also highlights the significance of effective toxicity management for early detection, monitoring, and treatment of ocular toxicity. Finally, this review explores potential strategies to mitigate ADC-associated ocular toxicity from a drug development perspective. A more comprehensive understanding of ocular toxicity, combined with innovative approaches to target selection, linker design, payload optimization, as well as the biological processes underlying\n                    <jats:italic>in vivo<\/jats:italic>\n                    interactions between ADCs and tissues, may enable the reduction of ocular toxicity and improvement of clinical outcomes in future ADC therapy.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1698458","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:27:14Z","timestamp":1777267634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review"],"prefix":"10.3389","volume":"17","author":[{"given":"Junxiang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Public Health Clinical Center of Chengdu","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01321-8","article-title":"Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials","volume":"41","author":"Takamizawa","year":"2023","journal-title":"Invest New Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftale.2023.11.003","article-title":"Ocular side effects of oncological therapies: Review","volume":"99","author":"Asencio-Dur\u00e1n","year":"2024","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2021.02.028","article-title":"Reversible HER2 antibody-drug conjugate-induced ocular toxicity","volume":"57","author":"Sharma","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.5070","article-title":"Eye safety risks of antibody-drug conjugate cancer therapies","volume":"144","author":"Kopinski","year":"2026","journal-title":"JAMA Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2373331","article-title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma","volume":"65","author":"Dimopoulos","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03649-z","article-title":"Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy","volume":"41","author":"Li","year":"2024","journal-title":"Pharm Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101111","article-title":"Antibody-drug conjugates: functional principles and applications in oncology and beyond","volume":"9","author":"Theocharopoulos","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2024.10.015","article-title":"Antibody-drug conjugates: the toxicities and adverse effects that emergency physicians must know","volume":"85","author":"Markides","year":"2025","journal-title":"Ann Emerg Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c19-00853","article-title":"Antibody-drug conjugate payloads; study of auristatin derivatives","volume":"68","author":"Akaiwa","year":"2020","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J Cell Physiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003162","article-title":"Dupilumab-induced, tralokinumab-induced, and belantamab mafodotin-induced adverse ocular events-incidence, etiology, and management","volume":"42","author":"Mickevicius","year":"2023","journal-title":"Cornea"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaf004","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2023.0069","article-title":"Antibody-drug conjugates and ocular toxicity","volume":"39","author":"Jaffry","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03261-y","article-title":"Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy","volume":"25","author":"Dom\u00ednguez-Llamas","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000001063","article-title":"Ocular toxicities associated with antibody drug conjugates","volume":"35","author":"Marshall","year":"2024","journal-title":"Curr Opin Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","article-title":"Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs)","volume":"12","author":"Lindgren","year":"2024","journal-title":"Curr Ophthalmol Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3414","article-title":"Antibody-drug conjugates: advancing from magic bullet to biological missile","volume":"30","author":"Veneziani","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"L\u00f3pez de S\u00e1","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155510","article-title":"Antibodydrug conjugates: the new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/ICO.0000000000002934","article-title":"Refractive shifts and changes in corneal curvature associated with antibody-drug conjugates","volume":"41","author":"Canestraro","year":"2022","journal-title":"Cornea"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01069-9","article-title":"Risk minimization of antibodydrug conjugates in oncology: a review","volume":"44","author":"Lievano","year":"2021","journal-title":"Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070474","article-title":"Antibody-drug conjugates in breast cancer: ascent to destiny and beyond-a 2023 review","volume":"30","author":"Xiao","year":"2023","journal-title":"Curr Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27622","article-title":"A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"B35","unstructured":"KADCYLA\u00ae (ado-trastuzumab emtansine) for injection, for intravenous use. Prescribing information\n          \n          2025"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100343","article-title":"How we treat patients with metastatic HER2-positive breast cancer","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495137","article-title":"Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2438748","article-title":"Post-marketing safety surveillance of ado-trastuzumab emtansine: a real-world data retrospective cohort study using disproportionality analysis","volume":"24","author":"Chen","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated Malignancies: a pharmacovigilance study based on the FAERS database","volume":"22","author":"Ma","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti-HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1186\/s12885-019-5986-5","article-title":"Lacrimal drainage system stenosis associated with trastuzumab emtansine (Kadcyla\u00ae, T-DM1) administration: a case report","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001117","article-title":"Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report anticancer drugs","volume":"32","author":"Papageorgiou","year":"2021","journal-title":"Anticancer Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)\u2013high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101738","article-title":"Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer","volume":"59","author":"Lang","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617","article-title":"Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)","volume":"15","author":"Mao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101547","article-title":"Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy","volume":"56","author":"File","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2021.10.012","article-title":"Corneal toxicity of mirvetuximab soravtansine: A case report","volume":"45","author":"Vuillemey","year":"2022","journal-title":"J Fr Ophtalmol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B53","unstructured":"Center for drug evaluation and research application number: 761121orig1s000 clinical review(s)\n          \n          2019"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","unstructured":"Center for drug evaluation and research application number: 761137orig1s000 risk assessment and risk mitigation review(s)\n          \n          2019"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37544","article-title":"Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database","volume":"10","author":"Zheng","year":"2024","journal-title":"Heliyon"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a european multicenter real-world patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020056","article-title":"Real-world insights into efficacy and safety of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma: findings, considerations, and future directions","volume":"31","author":"Endo","year":"2024","journal-title":"Curr Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102278","article-title":"Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study","volume":"23","author":"Niedersuess-Beke","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2962","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15443","article-title":"Tisotumab vedotin in Japanese patients with recurrent\/ metastatic cervical cancer: Results from the innovaTV 206 study","volume":"113","author":"Yonemori","year":"2022","journal-title":"Cancer Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101676","article-title":"Ocular surface disease related to tisotumab vedotin-tftv","volume":"57","author":"Lent-Schochet","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1419145","article-title":"Insights into uveitis from Brentuximab vedotin in refractory Hodgkin\u2019s lymphoma: a case report and brief review","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1978090","article-title":"Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate","volume":"63","author":"Costa","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101440","article-title":"Brentuximab vedotin induced uveitis","volume":"26","author":"Therssen","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3205\/oc000080","article-title":"Brentuximab vedotin related bilateral\u00a0Purtscher-like retinopathy unresponsive to pulse steroid therapy and intravitreal aflibercept injection","volume":"7","author":"Ayhan","year":"2017","journal-title":"GMS Ophthalmol cases"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322378","article-title":"Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases","volume":"20","author":"Tan","year":"2025","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"B76","unstructured":"Center for drug evaluation and research application number:761384Orig1s000 risk assessment and risk mitigation review(s)\n          \n          2025"},{"key":"B77","unstructured":"Disitamab vedotin for injection. Prescribing information\n          \n          2022"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study","volume":"200","author":"Shragai","year":"2023","journal-title":"Br J Haematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26728","article-title":"Corneal toxicity with belantamab mafodotin: multi-institutional real-life experience","volume":"97","author":"Mohan","year":"2022","journal-title":"Am J Hematol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-025-01226-8","article-title":"A real-world\u00a0experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma","volume":"15","author":"Dileo","year":"2025","journal-title":"Blood Cancer J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411829","article-title":"Real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma","volume":"24","author":"Ntanasis-Stathopoulos","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281772","article-title":"Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020\u201304 study","volume":"108","author":"albot","year":"2023","journal-title":"Haematologica"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14222","article-title":"Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study","volume":"113","author":"Roussel","year":"2024","journal-title":"Eur J Haematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40487-022-00212-5","article-title":"Real-world outcomes of belantamab mafodotin for relapsed\/refractory multiple myeloma (RRMM): preliminary results of a spanish expanded access program (EAP)","volume":"11","author":"Alegre","year":"2023","journal-title":"Oncol Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285893","article-title":"Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States","volume":"110","author":"Hultcrantz","year":"2025","journal-title":"Haematologica"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.5935\/0004-2749.2021-0358","article-title":"A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review","volume":"87","author":"Kurt","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-021-01172-5","article-title":"Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report","volume":"14","author":"Marquant","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B92","unstructured":"Center for drug evaluation and research application number: 761060orig1s000 761060orig2s000 clinical review(s)\n          \n          2016"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.01.009","article-title":"First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients","volume":"28","author":"Piccaluga","year":"2004","journal-title":"Leuk Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"B95","unstructured":"BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use. Prescribing information\n          \n          2024"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00128-1","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial","volume":"25","author":"Fehm","year":"2024","journal-title":"Lancet Oncol"},{"key":"B98","unstructured":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Prescribing information\n          \n          2025"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.7150\/jca.86746","article-title":"Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: a real-world, pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"J Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2439510","article-title":"Mining and analysis of adverse event signals of trastuzumab deruxtecan via real-world data of FDA adverse event reporting system database from 2019 to 2023","volume":"25","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"B108","unstructured":"TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection, for intravenous use. Prescribing information\n          \n          2025"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1276976","article-title":"Assessing real-world safety concerns of sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system","volume":"13","author":"Gui","year":"2023","journal-title":"Front Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14740338.2024.2430305","article-title":"Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database","volume":"24","author":"Yang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","article-title":"Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","volume":"18","author":"Ouyang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085680","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Fang","year":"2025","journal-title":"BMJ"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: a global phase I trial","volume":"42","author":"Yao","year":"2024","journal-title":"J Clin Oncol"},{"key":"B120","unstructured":"Trastuzumab rezetecan for injection. Prescribing information\n          \n          \n          \n          2025"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"B122","unstructured":"LUMOXITI\u00ae (moxetumomab pasudotox-tdfk) for injection, for intravenous use. Prescribing information\n          \n          2020"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head Neck"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177","article-title":"Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies","volume":"29","author":"Dy","year":"2024","journal-title":"Oncologist"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.2.4","article-title":"Tisotumab vedotin safety and tolerability in clinical practice: managing adverse events","volume":"14","author":"Arn","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.cn112152-20251013-00506","article-title":"Management of ocular adverse events associated with antibody-drug conjugates in the treatment of solid tumors: a consensus statement from Chinese experts (2025 edition)","volume":"48","year":"2026","journal-title":"Chin J Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody\u2013drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibodydrug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"B134","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40261-025-01447-6","article-title":"Risk of ophthalmotoxicity associated with antibody-drug conjugates: a systematic review and meta-analysis","volume":"45","author":"Feng","year":"2025","journal-title":"Clin Drug Investig"},{"key":"B135","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","article-title":"Treatment-related adverse events of antibody drug-conjugates in clinical trials","volume":"18","author":"Tan","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-01950-z","article-title":"Harnessing computational technologies to facilitate antibody-drug conjugate development","volume":"21","author":"Croitoru","year":"2025","journal-title":"Nat Chem Biol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"20525","DOI":"10.1038\/s41598-025-05555-3","article-title":"Linker-GPT: design of antibody-drug conjugates linkers with molecular generators and reinforcement learning","volume":"15","author":"Su","year":"2025","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1698458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:27:19Z","timestamp":1777267639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1698458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":138,"alternative-id":["10.3389\/fimmu.2026.1698458"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1698458","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1698458"}}